Document is current
Any future updates will be listed below
-
Authors
Li, Man
Yu, Xuexin
Ouyang, Shuqin
Chen, Xiaohong
Yu, Huiqi
Liu, Yuanji
Li, Ziwen
Yu, Chunhua
Kang, Rui https://orcid.org/0000-0003-2725-1574
Gaillet, Christine https://orcid.org/0000-0002-1208-1130
Colombeau, Ludovic https://orcid.org/0000-0001-5823-2603
Rodriguez, Raphaël https://orcid.org/0000-0001-7668-446X
Song, Libing https://orcid.org/0000-0002-5315-771X
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Tang, Daolin https://orcid.org/0000-0002-1903-6180
- License Information
-
More Information
Article History
Received: 18 May 2025
Accepted: 27 April 2026
First Online: 3 June 2026
Competing interests
: G.K. declares research contracts with Daiichi Sankyo, Eleor, Kaleido Biosciences, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro Biopharma, Tollys and VASCage; serves on the Board of Directors of the Bristol Myers Squibb Foundation France, and on scientific advisory boards for Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences/Centenara Labs; and is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio; and is the inventor of patents covering therapeutic targeting of ageing, cancer, cystic fibrosis and metabolic disorders, including one ‘Methods for weight reduction’ (US11905330B1) relevant to this work. G.K.’s brother, R. Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. G.K.’s wife, L. Zitvogel, has held research contracts with GSK, Incyte, Lytix Pharma, Kaleido Biosciences, Innovate Pharma, Daiichi Sankyo, PiLeJe, Merus, Transgene SA, 9M Life Sciences, Tusk Therapeutic and Roche; was on the on the Board of Directors of Transgene SA; is a cofounder of everImmune; and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. The other authors declare no competing interests.
